10-K: Ensysce Biosciences Reports Full Year 2024 Results, Highlights Clinical Progress and Financial Position

Ensysce Biosciences details its financial results for 2024 and provides an update on its clinical development programs focused on pain relief and abuse prevention.

Summary

• Ensysce Biosciences, a clinical-stage pharmaceutical company, reported its financial results for the year ended December 31, 2024.
• The company is focused on developing innovative solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose.
• Key product candidates include PF614 (a TAAP oxycodone prodrug) and PF614-MPAR (combining PF614 with nafamostat for overdose protection).
• The company received federal grant funding totaling $5.2 million in 2024, with $3.1 million from NIH related to the Phase 1 clinical trial for PF614-MPAR and $2.1 million from NIDA for preclinical development of its opioid use disorder-MPAR technology.
• The company's net loss for 2024 was $7.987 million, compared to a net loss of $10.626 million in 2023.
• Research and development expenses were $7.219 million in 2024, a decrease from $7.587 million in 2023.
• General and administrative expenses decreased to $4.721 million in 2024 from $5.361 million in 2023.
• As of December 31, 2024, the company had $3.502 million in cash and cash equivalents.
• The company states that its existing cash and cash equivalents will enable it to fund its operating expenses and capital expenditure requirements into the second quarter of 2025.
• The company will need to raise additional capital to continue to operate as a going concern.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are some positive developments, such as the Breakthrough Therapy designation and a decrease in net loss, the company's financial position remains precarious, with a need for additional funding and a going concern warning from its auditors.

Positives

• Federal grant funding increased from $2.231 million in 2023 to $5.210 million in 2024.
• Net loss decreased from $10.626 million in 2023 to $7.987 million in 2024.
• Research and development expenses decreased from $7.587 million in 2023 to $7.219 million in 2024.
• General and administrative expenses decreased from $5.361 million in 2023 to $4.721 million in 2024.
• PF614-MPAR was granted Breakthrough Therapy designation by the FDA in January 2024.

Negatives

• The company has incurred significant operating losses since inception and expects to continue to incur net losses for the foreseeable future.
• The company has limited revenue and does not expect to generate any revenue from the sale of products in the near future, if at all.
• The company will need to raise additional capital to continue to operate as a going concern.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is dependent on its ability to obtain adequate financing and achieve profitable operations.
• The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable.
• The company is dependent on third parties to manufacture its product candidates.
• The company may face litigation from third parties claiming that its products or business infringe, misappropriate, or otherwise violate their intellectual property rights.
• Cyber-attacks or other failures in the company's telecommunications or information technology systems could result in information theft, data corruption and significant disruption of its business operations.
• Raising additional capital in the public or private equity markets could cause dilution to the company's stockholders, adversely affect the market price of its common stock, restrict its operations or require it to relinquish rights to its technologies or product candidates.
• The company's internal controls over financial reporting may not meet all of the standards contemplated by Section 404 of Sarbanes-Oxley Act.
• Nasdaq may delist the company's common stock and/or its Public Warrants may not continue to trade on the OTC Pink Open Market.

Future Outlook

The company expects its expenses and capital requirements to increase substantially in connection with its ongoing development activities. The company states that its existing cash and cash equivalents will enable it to fund its operating expenses and capital expenditure requirements into the second quarter of 2025. The company will need to raise additional capital to continue to operate as a going concern.

Industry Context

The company operates in the competitive pharmaceutical industry, facing competition from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. The company is focused on developing innovative solutions for severe pain relief while reducing the potential for opioid misuse, abuse and overdose.

Comparison to Industry Standards

• The document mentions several competitors, including Purdue Pharma, LP, Collegium Pharmaceutical, Inc. and Vertex Pharmaceuticals Incorporated.
• The document notes that there are only four commercially available (in the United States) opioid drugs for chronic pain relief that have an abuse-deterrent label.
• The document states that Vertex has recently announced the approval of a non-opioid pain product, suzetrigine, that inhibits NaV1.8, but the clinical data provided to date has indicated that suzetrigine did not provide superior pain relief compared to the opioid control arm of the Phase 3 study.

Related Party Transactions

• As of December 31, 2024, the Company held a $ 0.2 million senior secured convertible promissory note plus accrued interest and 29,547 warrants exercisable for common stock at $ 23.51 per share issued to a board member in connection to the issuance of the 2023 Notes.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees may be affected by the company's ability to continue as a going concern and its need to manage expenses.
• Customers and patients may benefit from the company's development of safer pain relief options.
• Suppliers and creditors may be affected by the company's financial condition and its ability to meet its obligations.

Next Steps

• The meeting clarified the non-clinical and clinical Phase 3 study plans for the further development of PF614 which are expected to initiate in mid-2025.
• The study initiated in December 2024 and will continue through 2025.

Key Dates